STAR COMBO PHARMA LIMITED — Major Shareholding Notification 2020

May 28, 2020

Form603

Corporations Act 2001 Section 671B

Notice of initial substantial holder

	To Company Name/Scheme ACN/ARSN	Star Combo Pharma LimitedABN: 38 615 728 375
1.	Details of substantial holder (1)	Goldenstar Pharmaceutical Investment Limited
Name	ACN/ARSN (if applicable)	BVI Company Number: 2032444

The holder became a substantial holder on

26 / May / 2020

2. Details of voting power

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3)in on the date the substantial holder became a substantial holder are as follows:

Class of securities (4)	Number of securities	Person's votes (5)	Voting power (6)
Ordinary Shares	135,616,601	49.000.000	36.1%

3. Details of relevant interests

The nature of the relevant interest the substantial holder or an associate had in the following voting securities on the date the substantial holder became a substantial holder are as follows:

Holder of relevant interest	Nature of relevant interest	Class and number of securities
Goldenstar Pharmaceutical Investment Limited	Holder	49,000,000 Ordinary Shares

4. Details of present registered holders

The persons registered as holders of the securities referred to in paragraph3 above are as follows:

Holder of relevant interest	Registered holder of securities	Person entitled to be registeredas holder (8)	Class and number of securities
Goldenstar PharmaceuticalInvestment Limited	Goldenstar PharmaceuticalInvestment Limited	Goldenstar PharmaceuticalInvestment Limited	49,000,000 OrdinaryShares

5. Consideration

The consideration paid for each relevant interest referred to in paragraph3 above, and acquired in the four months prior to the day that the substantial holder became a substantial holder is as follows:

Holder of relevant interest	Date ofacquisition	Consideration		Class and number ofsecurities
		Cash	Non Cash
Goldenstar PharmaceuticalInvestment Limited	26 May 2020	$33,320,000	n/a	49,000,000 OrdinaryShares

6. Associates

The reasons the persons named in paragraph3 above are associates of the substantial holder are as follows:

7. Address

The addresses of persons named in this form are as follows:

Name	Address
Goldenstar PharmaceuticalInvestment Limited	Sea Meadow House, Blackburne Highway, (P.O. Box 116), RoadTown, Tortola, British Virgin Islands

Signature

Sian here ........ – Director Name: Han Tao

Date: 26 May 2020

DIRECTIONS

• If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the naries could be induded in an ann throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out inparagraph7of the form.
• See the definition of "associate" in section 9 of the Corporations Act 2001.
• See the definition of "relevant interest" in sections 608 and 671B (7) of the Corporations Act 2001.
• The voting shares of a company constitute one class unless divided into separate classes.
• The total number of votes attached to all the voting shares in the company or voting interests in the scheme (if any) that the person or an associate has a relevant interest in.
• The person's votes divided by the total votes in the body corporate or schememultiplied by 100.
• Include details of:
  • Any relevant agreement or other circumstances by which the relevant interest was acquired. If subsection671B(4)applies, a copy of any document setting out the $(a)$ terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
  • Any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to $(b)$ which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

See the definition of "relevant agreement" in section9 of the Corporations Act 2001.

• If the substantial holder is unable to determine the identity of the person (eg. if the relevant interest arises because of an option) write "unknown".
• Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a cortingency Details must be included of any benefit paid on behalf of the substantial holderor its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.